Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.83) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.83), Zacks reports. The company had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $0.54 million. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%.
Xenetic Biosciences Stock Performance
Shares of NASDAQ:XBIO traded down $0.14 during trading on Thursday, reaching $3.15. 59,989 shares of the stock traded hands, compared to its average volume of 7,299. Xenetic Biosciences has a 52-week low of $2.78 and a 52-week high of $5.97. The stock has a market cap of $4.85 million, a P/E ratio of -1.08 and a beta of 2.29. The stock has a 50-day moving average of $3.98 and a two-hundred day moving average of $3.98.
Xenetic Biosciences Company Profile
Further Reading
- Five stocks we like better than Xenetic Biosciences
- Following Congress Stock Trades
- Michael Burry’s Alibaba Bet and the Broader Market Implications
- Canada Bond Market Holiday: How to Invest and Trade
- Jeff Brown’s Exegesis AI Stock Picks
- How to Calculate Options Profits
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.